Largest pharmaceutical companies by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
AbbVie leads the 61 pharmaceutical companies ranked by total liabilities, at AED 503.9B, ahead of Pfizer (AED 445.8B) and Johnson & Johnson (AED 432.2B). Figures as of 18 Nov 2026, 17:48 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 61
- First
- AbbVieAED 503.9B
- Median
- AED 7.7B
- Combined market value
- AED 18.69T
- Countries
- 10
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | AED 503.9B | AED 1.87T | AED 1,057.10 | 1.71% down | 26% up | ||
| 2 | PfizerPFE · Health Care | AED 445.8B | AED 589.6B | AED 103.45 | 1.07% down | 14% up | ||
| 3 | Johnson & JohnsonJNJ · Health Care | AED 432.2B | AED 2.44T | AED 1,014.11 | 0.93% down | 38% up | ||
| 4 | Eli LillyLLY · Health Care | AED 315.7B | AED 4.55T | AED 5,104.32 | 1.82% down | 35% up | ||
| 5 | Merck & CoMRK · Health Care | AED 309.3B | AED 1.26T | AED 509.80 | 3.19% down | 51% up | ||
| 6 | Bristol-Myers SquibbBMY · Health Care | AED 262.7B | AED 450.6B | AED 220.43 | 2.18% down | 34% up | ||
| 7 | AstraZenecaAZN · Health Care | AED 240B | AED 1.02T | AED 659.00 | 1.56% down | 2% up | ||
| 8 | NovartisNVS · Health Care | AED 236.5B | AED 1.08T | AED 572.90 | 1.98% down | 25% up | ||
| 9 | SanofiSNY · Health Care | AED 224.5B | AED 417.2B | AED 173.75 | 0.47% down | 4% down | ||
| 10 | GSKGSK · Health Care | AED 220.2B | AED 359.2B | AED 179.20 | 0.91% down | 6% up | ||
| 11 | Novo NordiskNVO · Health Care | AED 190.1B | AED 641.1B | AED 145.47 | 2.69% down | 17% down | ||
| 12 | Takeda PharmaceuticalTAK · Health Care | AED 185.9B | AED 251B | AED 78.56 | 1.16% down | 54% up | ||
| 13 | Abbott LaboratoriesABT · Health Care | AED 124.7B | AED 665.2B | AED 384.08 | 0.13% down | 17% down | ||
| 14 | Teva Pharmaceutical IndustriesTEVA · Health Care | AED 120.6B | AED 181B | AED 155.14 | 0.89% down | 74% up | ||
| 15 | ViatrisVTRS · Health Care | AED 82.6B | AED 87.3B | AED 76.16 | 1.39% up | 96% up | ||
| 16 | GrifolsGRFS · Health Care | AED 49.3B | AED 21.2B | AED 31.09 | 1.91% down | 1% up | ||
| 17 | ZoetisZTS · Health Care | AED 44.6B | AED 126.6B | AED 311.51 | 1.60% up | 29% down | ||
| 18 | Royalty PharmaRPRX · Health Care | AED 36.4B | AED 146.4B | AED 254.53 | 0.90% up | 78% up | ||
| 19 | Regeneron PharmaceuticalsREGN · Health Care | AED 34.2B | AED 360.7B | AED 3,486.46 | 0.89% down | 36% up | ||
| 20 | Jazz PharmaceuticalsJAZZ · Health Care | AED 27B | AED 58.1B | AED 905.15 | 2.38% up | 37% up | ||
| 21 | GenmabGMAB · Health Care | AED 25.8B | AED 116.6B | AED 189.15 | 0.89% down | 70% up | ||
| 22 | Vertex PharmaceuticalsVRTX · Health Care | AED 25.6B | AED 499.1B | AED 1,968.45 | 0.33% up | 27% up | ||
| 23 | Elanco Animal HealthELAN · Health Care | AED 25B | AED 49.2B | AED 98.47 | 3.71% up | 20% up | ||
| 24 | Alnylam PharmaceuticalsALNY · Health Care | AED 15.3B | AED 74.8B | AED 558.72 | 2.80% down | 66% down | ||
| 25 | BeOne MedicinesONC · Health Care | AED 14.1B | AED 170.1B | AED 1,489.58 | 1.86% down | 17% up | ||
| 26 | Amneal PharmaceuticalsAMRX · Health Care | AED 13.5B | AED 28.1B | AED 80.66 | 3.98% up | 83% up | ||
| 27 | PTC TherapeuticsPTCT · Health Care | AED 11.4B | AED 18.6B | AED 222.10 | 0.18% up | 20% down | ||
| 28 | Ionis PharmaceuticalsIONS · Health Care | AED 11.1B | AED 16.9B | AED 101.34 | 2.34% up | 64% down | ||
| 29 | BridgeBio PharmaBBIO · Health Care | AED 11.1B | AED 55.8B | AED 286.19 | 1.46% up | 17% up | ||
| 30 | Dr. Reddy's LaboratoriesRDY · Health Care | AED 7.8B | AED 46B | AED 55.15 | 1.52% up | 5% up | ||
| 31 | CytokineticsCYTK · Health Care | AED 7.7B | AED 26.4B | AED 189.69 | 0.01% down | 20% down | ||
| 32 | Ascendis PharmaASND · Health Care | AED 6B | AED 65.4B | AED 997.45 | 0.14% up | 28% up | ||
| 33 | InsmedINSM · Health Care | AED 5.6B | AED 97.5B | AED 444.27 | 0.74% down | 40% down | ||
| 34 | BioMarin PharmaceuticalBMRN · Health Care | AED 5.5B | AED 43.1B | AED 222.71 | 3.63% up | 11% up | ||
| 35 | Arrowhead PharmaceuticalsARWR · Health Care | AED 3.2B | AED 22.6B | AED 159.86 | 1.24% up | 10% up | ||
| 36 | United TherapeuticsUTHR · Health Care | AED 2.9B | AED 90.9B | AED 2,133.99 | 0.53% down | 23% up | ||
| 37 | Legend BiotechLEGN · Health Care | AED 2.7B | AED 11.5B | AED 59.54 | 0.62% up | 42% down | ||
| 38 | AlkermesALKS · Health Care | AED 2.5B | AED 28.9B | AED 171.97 | 3.01% up | 58% up | ||
| 39 | Madrigal PharmaceuticalsMDGL · Health Care | AED 2.4B | AED 34.7B | AED 1,493.29 | 3.65% down | 24% down | ||
| 40 | Axsome TherapeuticsAXSM · Health Care | AED 2.2B | AED 25.8B | AED 491.12 | 1.64% down | 7% down | ||
| 41 | Ligand PharmaceuticalsLGND · Health Care | AED 2B | AED 22.1B | AED 1,104.48 | 2.35% up | 43% up | ||
| 42 | Mirum PharmaceuticalsMIRM · Health Care | AED 1.9B | AED 22.1B | AED 338.24 | 0.15% up | 31% up | ||
| 43 | Travere TherapeuticsTVTX · Health Care | AED 1.8B | AED 18.1B | AED 188.16 | 0.25% up | 44% up | ||
| 44 | Roivant SciencesROIV · Health Care | AED 1.5B | AED 102.9B | AED 142.01 | 0.12% down | 90% up | ||
| 45 | TG TherapeuticsTGTX · Health Care | AED 1.5B | AED 36.8B | AED 243.24 | 5.61% up | 107% up | ||
| 46 | Cogent BiosciencesCOGT · Health Care | AED 1.1B | AED 18.1B | AED 103.76 | 1.44% up | 20% down | ||
| 47 | Rhythm PharmaceuticalsRYTM · Health Care | AED 771.9M | AED 30.3B | AED 437.44 | 2.14% up | 13% up | ||
| 48 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | AED 720M | AED 27.6B | AED 350.85 | 0.44% up | 126% up | ||
| 49 | Corcept TherapeuticsCORT · Health Care | AED 693.6M | AED 27.5B | AED 251.06 | 2.45% down | 8% down | ||
| 50 | ABIVAXABVX · Health Care | AED 526.2M | AED 27B | AED 308.56 | 2.33% up | 27% down | ||
| 51 | Definium TherapeuticsDFTX · Health Care | AED 395.8M | AED 14.6B | AED 106.73 | 1.09% down | 169% up | ||
| 52 | Summit TherapeuticsSMMT · Health Care | AED 339.1M | AED 31.3B | AED 39.15 | 0.09% down | 36% down | ||
| 53 | ErascaERAS · Health Care | AED 260.7M | AED 17.2B | AED 48.89 | 4.18% down | 403% up | ||
| 54 | Spyre TherapeuticsSYRE · Health Care | AED 229.7M | AED 34B | AED 357.80 | 3.84% up | 286% up | ||
| 55 | Praxis Precision MedicinesPRAX · Health Care | AED 219.5M | AED 31.7B | AED 1,133.29 | 1.15% up | 61% up | ||
| 56 | Protagonist TherapeuticsPTGX · Health Care | AED 196.4M | AED 30.1B | AED 460.66 | 0.60% up | 46% up | ||
| 57 | Dianthus TherapeuticsDNTH · Health Care | AED 137.8M | AED 18B | AED 320.46 | 0.31% up | 113% up | ||
| 58 | Edgewise TherapeuticsEWTX · Health Care | AED 111.5M | AED 16.8B | AED 153.78 | 0.40% down | 88% up | ||
| 59 | Oruka TherapeuticsORKA · Health Care | AED 61.3M | AED 24.4B | AED 359.21 | 1.54% up | 241% up | ||
| 60 | Belite BioBLTE · Health Care | AED 37M | AED 23.6B | AED 581.90 | 0.45% up | 31% up | ||
| 61 | VeradermicsMANE · Health Care | AED 33.6M | AED 19.2B | AED 455.40 | 1.31% down | 233% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6729 AED).
Questions and answers
Which pharmaceutical companies rank first by total liabilities?
AbbVie (AED 503.9B), Pfizer (AED 445.8B) and Johnson & Johnson (AED 432.2B) are the top three of the 61 pharmaceutical companies ranked by total liabilities as of 18 Nov 2026, 17:48 UTC.
How many pharmaceutical companies are in this ranking?
61 are ranked by total liabilities.
What are these pharmaceutical companies worth together?
The 61 pharmaceutical companies ranked by total liabilities have a combined market value of AED 18.69T as of 18 Nov 2026, 17:48 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies by total liabilities”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.